InterveXion
is an Arkansas-based biopharmaceutical company that develops and commercializes novel products for the treatment of addiction disorders... Read moreInterveXion
is an Arkansas-based biopharmaceutical company that develops and commercializes novel products for the treatment of addiction disorders... Read more
News
Jul 05, 2022
EIN Presswire
Press Release: InterveXion : InterveXion Enrolls First Patient in OUTLAST, a Phase 2 Study of IXT-m200 in Methamphetamine Use Disorder
Apr 04, 2022
FirstWord Pharma
InterveXion: InterveXion to Present Positive Phase 2 STAMPOUT Study Data at Upcoming 'College on Problems in Drug Dependence' Meeting
Nov 01, 2021
Talk Business & Politics
InterveXion: UAMS startup lands $13.8 million grant for Phase 2 trial to help meth addicts
Oct 04, 2021
EIN Presswire
Press Release: InterveXion : InterveXion Therapeutics Awarded Federal Grant to Fund Phase 2 Study for Methamphetamine Use Disorder
Sep 20, 2021
EIN Presswire
Press Release: InterveXion : InterveXion Enrolls First Patient in Meth-OD, a Phase 2 Study of IXT-m200 in Methamphetamine Overdose
Apr 19, 2021
EIN Presswire
Press Release: InterveXion : InterveXion Announces Positive Data in Phase 2 Study of IXT-m200 in Participants with Methamphetamine Use Disorder
Oct 05, 2020
EIN Presswire
Press Release: InterveXion : InterveXion Therapeutics Awarded Federal Grant to Fund Phase 2 Study for Methamphetamine Overdose
Aug 12, 2019
EIN Presswire
Press Release: InterveXion : InterveXion Therapeutics Receives Japanese Patent for IXT-m200 (Anti-Methamphetamine Antibody)
Jul 29, 2019
EIN Presswire
Press Release: InterveXion : InterveXion Announces Positive Results from Pre-Specified Interim Review of Phase 2 STAMPOUT Study
May 20, 2019
Arkansas Business
InterveXion: Keith Ward to Lead Little Rock's InterveXion Therapeutics
InterveXion Competitors
1
2
3
4
5
6
7
8
9
10